Immunic, Inc. Engages in Critical Conferences This April
Immunic, Inc. (Nasdaq: IMUX) is poised to actively participate in vital scientific and industry conferences in April, enhancing its presence within the biotechnology sector. The company focuses on developing clinically advanced, orally administered small molecule therapies aimed at treating chronic inflammatory and autoimmune diseases. This strategic involvement allows Immunic to showcase its innovative research and connect with other leaders in the field.
Upcoming Conference Participation
The company will be part of the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5 to 9. This meeting presents an opportunity for Immunic's management and team members to engage with peers, discuss advancements in neuroscience, and present their unique insights. Immunic will have a dedicated booth at this event located at booth #2233 in San Diego, California, where they will be readily available to answer questions and share their clinical pipeline details.
German Biotech Days 2025 Participation
Following the AAN meeting, Immunic will present at the German Biotech Days 2025, happening on April 9 and 10. Dr. Hella Kohlhof, the Chief Scientific Officer of Immunic, is set to deliver a presentation titled "Vidofludimus Calcium – Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention." This presentation will highlight the company’s lead asset, vidofludimus calcium (IMU-838), and the company’s impressive journey toward reaching late-stage clinical trials. The symposium aims to illustrate Immunic’s progress in the biotechnology domain and foster collaborations within the community.
Details of the Symposium Session
During the symposium, which will take place on Wednesday, April 9, from 2:20 to 3:30 pm CET (8:20 to 9:30 am ET), Immunic will discuss its innovative therapies and the impact they can have on healthcare. The session will be held at Saal 2, where attendees can engage directly with Immunic’s findings and plans for the future.
About Immunic, Inc.
Immunic, Inc. stands at the forefront of biotechnology, developing a compelling pipeline of therapies for chronic inflammatory and autoimmune diseases. Their most notable program, vidofludimus calcium (IMU-838), is currently being evaluated in both phase 2 and phase 3 clinical trials, targeting conditions such as relapsing and progressive multiple sclerosis. It has shown encouraging therapeutic effects in previous studies for patients experiencing various forms of multiple sclerosis and ulcerative colitis. This first-in-class Nurr1 activator not only targets neuroprotection but also exhibits significant anti-inflammatory and anti-viral properties.
Additionally, Immunic is advancing the development of other promising compounds, including IMU-856, which focuses on restoring intestinal barrier function, and IMU-381, aimed at addressing gastrointestinal diseases. These therapies may become essential treatments for various conditions like celiac disease and inflammatory bowel diseases.
Contact Information for Inquiries
For those seeking more information regarding Immunic, Inc. or its pipeline, the company remains available through various channels:
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
Frequently Asked Questions
What is the main focus of Immunic, Inc.?
Immunic, Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases with a clinical pipeline of small molecule treatments.
What events is Immunic participating in?
In April, Immunic will participate in the American Academy of Neurology (AAN) Annual Meeting and the German Biotech Days.
Who will present at the German Biotech Days?
Dr. Hella Kohlhof, the Chief Scientific Officer, will present key insights on vidofludimus calcium.
What is vidofludimus calcium?
Vidofludimus calcium is Immunic's lead asset designed to activate nuclear receptor-related 1 (Nurr1) and address conditions like multiple sclerosis.
How can I contact Immunic for more information?
Inquiries can be directed to their investor relations team or through their media contacts available on their official website.
